desai et al., circulation 2013
DESCRIPTION
Lp(a) reduction after different dosing schemes of PCSK9 inhibition. AMG 145 Q2W. AMG 145 Q4W. 0. 70mg (n=75). 105mg (n=76). 140mg (n=73). 280mg (n=78). 350mg (n=79). 420mg (n=77). -10. -18.2. -18.0. LS Mean % change in Lp(a) from baseline to week 12. -20. -22.8. - PowerPoint PPT PresentationTRANSCRIPT
Desai et al., Circulation 2013
Lp(a) reduction after different dosing schemes of PCSK9 inhibition
LS
Me
an %
ch
ang
e in
Lp
(a)
fro
m b
as
elin
e t
o w
eek
12
AMG 145 Q2W AMG 145 Q4W
70mg(n=75)
280mg(n=78)
105mg(n=76)
140mg(n=73)
350mg(n=79)
420mg(n=77)
P<0.001 for each dose vs. placebo
P<0.001 for each dose vs. placebo
-18
-32.3-32.1
-18.0 -18.2
-22.8 -23.1
0
-10
-20
-30
-40